{"id":23644,"date":"2020-06-20T02:44:59","date_gmt":"2020-06-20T02:44:59","guid":{"rendered":"https:\/\/www.gkseries.com\/blog\/?p=23644"},"modified":"2020-06-20T02:45:01","modified_gmt":"2020-06-20T02:45:01","slug":"shilpa-medicare-launched-the-anti-cancer-drug-dasashil","status":"publish","type":"post","link":"https:\/\/www.gkseries.com\/blog\/shilpa-medicare-launched-the-anti-cancer-drug-dasashil\/","title":{"rendered":"Shilpa Medicare launched the anti-cancer drug Dasashil"},"content":{"rendered":"\n<p><strong>Shilpa Medicare<\/strong>&nbsp;launched its generic version of<strong>&nbsp;cancer drug Dasatinib.<\/strong>&nbsp;The monthly therapy cost of&nbsp;<strong>Rs.6,440.&nbsp;<\/strong>The company launched the Indian branded generic of Dasatinib, an anti-cancer drug with a brand name<strong>&nbsp;&#8220;Dasashil.&#8221;<\/strong><br><br><strong>Dasashil:<\/strong><br>\u2666 Dasashil, the branded generic anti-cancer drug, will be available in all dosage strengths of 20 mg, 50 mg, 70 mg, and 100 mg tablets.&nbsp;<br>\u2666 The drug is used for the treatment of Chronic Myeloid Leukaemia (CML).&nbsp;<br>\u2666 Dasashil will revolutionize the treatment by ensuring to make therapy available for more Indian patients due to increased affordability.&nbsp;<br>\u2666 The products are being manufactured and supplied from the company&#8217;s US Food and Drug Administration (FDA) approved manufacturing facility.<br>\u2666 The drug can benefit around 10,000 to 15,000 new patients of CML in India.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Shilpa Medicare&nbsp;launched its generic version of&nbsp;cancer drug Dasatinib.&nbsp;The monthly therapy cost of&nbsp;Rs.6,440.&nbsp;The company launched the Indian branded generic of Dasatinib, an anti-cancer drug with a brand name&nbsp;&#8220;Dasashil.&#8221; Dasashil:\u2666 Dasashil, the branded generic anti-cancer drug, will be available in all dosage strengths of 20 mg, 50 mg, 70 mg, and 100 mg tablets.&nbsp;\u2666 The drug is [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":23645,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1012],"tags":[],"offerexpiration":[],"class_list":["post-23644","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-current-affairs-april-2020"],"_links":{"self":[{"href":"https:\/\/www.gkseries.com\/blog\/wp-json\/wp\/v2\/posts\/23644","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.gkseries.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.gkseries.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.gkseries.com\/blog\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.gkseries.com\/blog\/wp-json\/wp\/v2\/comments?post=23644"}],"version-history":[{"count":1,"href":"https:\/\/www.gkseries.com\/blog\/wp-json\/wp\/v2\/posts\/23644\/revisions"}],"predecessor-version":[{"id":23646,"href":"https:\/\/www.gkseries.com\/blog\/wp-json\/wp\/v2\/posts\/23644\/revisions\/23646"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.gkseries.com\/blog\/wp-json\/wp\/v2\/media\/23645"}],"wp:attachment":[{"href":"https:\/\/www.gkseries.com\/blog\/wp-json\/wp\/v2\/media?parent=23644"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.gkseries.com\/blog\/wp-json\/wp\/v2\/categories?post=23644"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.gkseries.com\/blog\/wp-json\/wp\/v2\/tags?post=23644"},{"taxonomy":"offerexpiration","embeddable":true,"href":"https:\/\/www.gkseries.com\/blog\/wp-json\/wp\/v2\/offerexpiration?post=23644"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}